vx765 Search Results


96
MedChemExpress caspase 1 inhibitor belnacasan
Caspase 1 Inhibitor Belnacasan, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/caspase 1 inhibitor belnacasan/product/MedChemExpress
Average 96 stars, based on 1 article reviews
caspase 1 inhibitor belnacasan - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

96
InvivoGen vx765
Figure 6 Caspase 8 contributes to the pyroptosis induced by PARP inhibition. Ratios of PI+ annexin V+ OVCAR8 (A), A2780 (B), and primary homologous recombination deficiency (HRD) ovarian cancer (OC) tumor cells (C) on niraparib exposure in the presence or absence of caspase inhibitors, including <t>VX765,</t> Z-DEVD-FMK, Z-IETD-FMK, and Z-VAD-FMK. (D) Determination of activated caspase 3 and caspase 8 levels in OVCAR8 and A2780 cells after olaparib and niraparib treatment by flow cytometry. Histological analyses of activated caspase 3 and caspase 8 in OC patient-derived xenograft (PDX) tumors (E) and triple-negative breast cancer (TNBC) PDX tumors (F) with or without niraparib exposure (n=5/6). (G) Western blotting analyses of the cleavage of caspase 8/3 and GSDMD/E in OVCAR8 and A2780 cells on niraparib treatment in the presence or absence of caspase inhibitors, including Z-DEVD-FMK, Z-IETD-FMK, and Z-VAD-FMK. Representative images of OVCAR8 (H) and A2780 cells (I) on niraparib treatment in the presence or absence of caspase inhibitors, including VX765, Z-DEVD-FMK, and Z-IETD-FMK. Mean values±SEM. *P<0.05, **p<0.01, and ***p< 0.001 by Student’s t-test in (A–C) and (E,F).
Vx765, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vx765/product/InvivoGen
Average 96 stars, based on 1 article reviews
vx765 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

94
TargetMol vx 765
Ferroptosis inhibitor Fer-1 inhibited MHV-A59 induced syncytia and membrane damage. (A and B) Primary peritoneal macrophages (PMs) were infected with MHV-A59 at 0.05 MOI. After 2 hours of infection, cells were treated with Fer-1 (10 μM). After 24 hours of infection, cells were imaged using CytoSMART system (A) and cell confluence was evaluated using the CytoSMART website (B). (C) PMs were infected as described in (A) and were stained with propidium iodide (PI). After staining cells were imaged under fluorescence microscope. (D) PMs were infected as described in (A), followed by the treatment with Fer-1 (10 μM), z-DEVD-FMK (25 μM), <t>VX-765</t> (30 μM) or GSK-872 (10 μM). Cells were stained with PI and imaged under fluorescence microscope. (E) Scale bars: For (A) and (C), 200 μm. For (D), 100 μm. Data from two independent experiments was shown. *, p < 0.05; Student’s t- test. See also Video S1.
Vx 765, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vx 765/product/TargetMol
Average 94 stars, based on 1 article reviews
vx 765 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
Tocris vx765
Inflammasome inhibitors delay VPRH-mediated cell death. Approximately 3.5*10 4 wild-type BMDMs were seeded into 96-well plates in triplicate, and were primed using LPS (100 ng/ml) for 3 h prior to infection with V. proteolyticus mutants at MOI 50. Where indicated, inflammasome inhibitors – <t>Vx765</t> (25 μM), MCC950 (20 μM), or NSA (20 μM), with the addition of propidium iodide (PI) (1 μg/ml), were added to the cells 30 min prior to bacterial infection. DMSO was added as the solvent control. (A) PI uptake was assessed using real-time microscopy (IncucyteZOOM) and then graphed as the percentage of PI-positive cells normalized to the number of cells in wells. Data are presented as the mean ± SD; n = 3. (B) Summary of normalized AUC for three independent biological experiments shown in panel A. (C-E) Cell lysates and supernatants from experiments described in A were collected 6 h post-infection. (C, D) IL-1β (C) and TNFα (D) secretion were measured using commercial ELISA kits. (E, F) Inflammasome components, caspase-1 (Casp1), GSDMD, and IL-1β cleavage were detected in BMDM lysates (E) and supernatants (F) using immunoblots (the numbers on the right of each blot indicate the blot number). The data in A, E, and F are representative of 3 independent experiments. Statistical comparisons in B, C and D between the different bacterial mutants and inflammasome inhibitors were carried using RM two-way ANOVA, followed by Tukey's multiple comparison test; the results are presented as the mean (bars) ± SD of 3 independent experiments; significant differences are denoted only for comparisons between inhibitors in each infected strain; * P < 0.05, ** P < 0.01.
Vx765, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vx765/product/Tocris
Average 94 stars, based on 1 article reviews
vx765 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

90
Toronto Research Chemicals vx765
Inflammasome inhibitors delay VPRH-mediated cell death. Approximately 3.5*10 4 wild-type BMDMs were seeded into 96-well plates in triplicate, and were primed using LPS (100 ng/ml) for 3 h prior to infection with V. proteolyticus mutants at MOI 50. Where indicated, inflammasome inhibitors – <t>Vx765</t> (25 μM), MCC950 (20 μM), or NSA (20 μM), with the addition of propidium iodide (PI) (1 μg/ml), were added to the cells 30 min prior to bacterial infection. DMSO was added as the solvent control. (A) PI uptake was assessed using real-time microscopy (IncucyteZOOM) and then graphed as the percentage of PI-positive cells normalized to the number of cells in wells. Data are presented as the mean ± SD; n = 3. (B) Summary of normalized AUC for three independent biological experiments shown in panel A. (C-E) Cell lysates and supernatants from experiments described in A were collected 6 h post-infection. (C, D) IL-1β (C) and TNFα (D) secretion were measured using commercial ELISA kits. (E, F) Inflammasome components, caspase-1 (Casp1), GSDMD, and IL-1β cleavage were detected in BMDM lysates (E) and supernatants (F) using immunoblots (the numbers on the right of each blot indicate the blot number). The data in A, E, and F are representative of 3 independent experiments. Statistical comparisons in B, C and D between the different bacterial mutants and inflammasome inhibitors were carried using RM two-way ANOVA, followed by Tukey's multiple comparison test; the results are presented as the mean (bars) ± SD of 3 independent experiments; significant differences are denoted only for comparisons between inhibitors in each infected strain; * P < 0.05, ** P < 0.01.
Vx765, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vx765/product/Toronto Research Chemicals
Average 90 stars, based on 1 article reviews
vx765 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
DSK Biopharma Inc vx-765
Inflammasome inhibitors delay VPRH-mediated cell death. Approximately 3.5*10 4 wild-type BMDMs were seeded into 96-well plates in triplicate, and were primed using LPS (100 ng/ml) for 3 h prior to infection with V. proteolyticus mutants at MOI 50. Where indicated, inflammasome inhibitors – <t>Vx765</t> (25 μM), MCC950 (20 μM), or NSA (20 μM), with the addition of propidium iodide (PI) (1 μg/ml), were added to the cells 30 min prior to bacterial infection. DMSO was added as the solvent control. (A) PI uptake was assessed using real-time microscopy (IncucyteZOOM) and then graphed as the percentage of PI-positive cells normalized to the number of cells in wells. Data are presented as the mean ± SD; n = 3. (B) Summary of normalized AUC for three independent biological experiments shown in panel A. (C-E) Cell lysates and supernatants from experiments described in A were collected 6 h post-infection. (C, D) IL-1β (C) and TNFα (D) secretion were measured using commercial ELISA kits. (E, F) Inflammasome components, caspase-1 (Casp1), GSDMD, and IL-1β cleavage were detected in BMDM lysates (E) and supernatants (F) using immunoblots (the numbers on the right of each blot indicate the blot number). The data in A, E, and F are representative of 3 independent experiments. Statistical comparisons in B, C and D between the different bacterial mutants and inflammasome inhibitors were carried using RM two-way ANOVA, followed by Tukey's multiple comparison test; the results are presented as the mean (bars) ± SD of 3 independent experiments; significant differences are denoted only for comparisons between inhibitors in each infected strain; * P < 0.05, ** P < 0.01.
Vx 765, supplied by DSK Biopharma Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vx-765/product/DSK Biopharma Inc
Average 90 stars, based on 1 article reviews
vx-765 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
ApexBio vx-765
Inflammasome inhibitors delay VPRH-mediated cell death. Approximately 3.5*10 4 wild-type BMDMs were seeded into 96-well plates in triplicate, and were primed using LPS (100 ng/ml) for 3 h prior to infection with V. proteolyticus mutants at MOI 50. Where indicated, inflammasome inhibitors – <t>Vx765</t> (25 μM), MCC950 (20 μM), or NSA (20 μM), with the addition of propidium iodide (PI) (1 μg/ml), were added to the cells 30 min prior to bacterial infection. DMSO was added as the solvent control. (A) PI uptake was assessed using real-time microscopy (IncucyteZOOM) and then graphed as the percentage of PI-positive cells normalized to the number of cells in wells. Data are presented as the mean ± SD; n = 3. (B) Summary of normalized AUC for three independent biological experiments shown in panel A. (C-E) Cell lysates and supernatants from experiments described in A were collected 6 h post-infection. (C, D) IL-1β (C) and TNFα (D) secretion were measured using commercial ELISA kits. (E, F) Inflammasome components, caspase-1 (Casp1), GSDMD, and IL-1β cleavage were detected in BMDM lysates (E) and supernatants (F) using immunoblots (the numbers on the right of each blot indicate the blot number). The data in A, E, and F are representative of 3 independent experiments. Statistical comparisons in B, C and D between the different bacterial mutants and inflammasome inhibitors were carried using RM two-way ANOVA, followed by Tukey's multiple comparison test; the results are presented as the mean (bars) ± SD of 3 independent experiments; significant differences are denoted only for comparisons between inhibitors in each infected strain; * P < 0.05, ** P < 0.01.
Vx 765, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vx-765/product/ApexBio
Average 90 stars, based on 1 article reviews
vx-765 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Cayman Chemical vx765
(A) Schematic of the experiment to assess DPP9-CARD8 ternary complex displacement in cells. (B) HEK 293TCASP1+GSDMD cells were transiently transfected plasmids encoding dTAG-CARD8ZUC and the isolated FIINDSA 48 h prior to treatment with dTAG-13 (500 nM), VbP (10 μM), MeBs (10 μM), or the combination for 6 h. Samples were collected and analyzed by immunoblotting and LDH release. (C) DPP8−/−/DPP9−/− THP-1 cells were treated with MeBs (10 μM) and/or bortezomib (Bort., 10 μM) for 8 h before LDH and immunoblot analyses. (D and E) CARD8−/− THP-1 cells stably containing doxycycline (DOX)-inducible CARD8 WT, E274R, and/or S297A were induced with 100 ng/mL DOX for 16 h prior to treatment with VbP (10 μM), MeBs (10 μM), <t>VX765</t> (50 μM), Bort. (10 μM), and/or MG132 (10 μM) for 6 h. Samples were then collected for LDH release and immunoblot analyses. Note in (D) that immunoblot and LDH analyses were performed separately. Data are means ± SEM of three biological replicates. All data, including immunoblots, are representative of three or more independent experiments. ***p < 0.001, **p < 0.01, *p < 0.05 by two-sided Student’s t test. n.s., not significant. See also Figure S2.
Vx765, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vx765/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
vx765 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Adooq Bioscience LLC caspase-1 inhibitor vx765
(A) Schematic of the experiment to assess DPP9-CARD8 ternary complex displacement in cells. (B) HEK 293TCASP1+GSDMD cells were transiently transfected plasmids encoding dTAG-CARD8ZUC and the isolated FIINDSA 48 h prior to treatment with dTAG-13 (500 nM), VbP (10 μM), MeBs (10 μM), or the combination for 6 h. Samples were collected and analyzed by immunoblotting and LDH release. (C) DPP8−/−/DPP9−/− THP-1 cells were treated with MeBs (10 μM) and/or bortezomib (Bort., 10 μM) for 8 h before LDH and immunoblot analyses. (D and E) CARD8−/− THP-1 cells stably containing doxycycline (DOX)-inducible CARD8 WT, E274R, and/or S297A were induced with 100 ng/mL DOX for 16 h prior to treatment with VbP (10 μM), MeBs (10 μM), <t>VX765</t> (50 μM), Bort. (10 μM), and/or MG132 (10 μM) for 6 h. Samples were then collected for LDH release and immunoblot analyses. Note in (D) that immunoblot and LDH analyses were performed separately. Data are means ± SEM of three biological replicates. All data, including immunoblots, are representative of three or more independent experiments. ***p < 0.001, **p < 0.01, *p < 0.05 by two-sided Student’s t test. n.s., not significant. See also Figure S2.
Caspase 1 Inhibitor Vx765, supplied by Adooq Bioscience LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/caspase-1 inhibitor vx765/product/Adooq Bioscience LLC
Average 90 stars, based on 1 article reviews
caspase-1 inhibitor vx765 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Vertex Pharmaceuticals vx-765
(A) Schematic of the experiment to assess DPP9-CARD8 ternary complex displacement in cells. (B) HEK 293TCASP1+GSDMD cells were transiently transfected plasmids encoding dTAG-CARD8ZUC and the isolated FIINDSA 48 h prior to treatment with dTAG-13 (500 nM), VbP (10 μM), MeBs (10 μM), or the combination for 6 h. Samples were collected and analyzed by immunoblotting and LDH release. (C) DPP8−/−/DPP9−/− THP-1 cells were treated with MeBs (10 μM) and/or bortezomib (Bort., 10 μM) for 8 h before LDH and immunoblot analyses. (D and E) CARD8−/− THP-1 cells stably containing doxycycline (DOX)-inducible CARD8 WT, E274R, and/or S297A were induced with 100 ng/mL DOX for 16 h prior to treatment with VbP (10 μM), MeBs (10 μM), <t>VX765</t> (50 μM), Bort. (10 μM), and/or MG132 (10 μM) for 6 h. Samples were then collected for LDH release and immunoblot analyses. Note in (D) that immunoblot and LDH analyses were performed separately. Data are means ± SEM of three biological replicates. All data, including immunoblots, are representative of three or more independent experiments. ***p < 0.001, **p < 0.01, *p < 0.05 by two-sided Student’s t test. n.s., not significant. See also Figure S2.
Vx 765, supplied by Vertex Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vx-765/product/Vertex Pharmaceuticals
Average 90 stars, based on 1 article reviews
vx-765 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
ChemieTek LLC caspase-1 inhibitor vx-765 ct-vx765
(A) Schematic of the experiment to assess DPP9-CARD8 ternary complex displacement in cells. (B) HEK 293TCASP1+GSDMD cells were transiently transfected plasmids encoding dTAG-CARD8ZUC and the isolated FIINDSA 48 h prior to treatment with dTAG-13 (500 nM), VbP (10 μM), MeBs (10 μM), or the combination for 6 h. Samples were collected and analyzed by immunoblotting and LDH release. (C) DPP8−/−/DPP9−/− THP-1 cells were treated with MeBs (10 μM) and/or bortezomib (Bort., 10 μM) for 8 h before LDH and immunoblot analyses. (D and E) CARD8−/− THP-1 cells stably containing doxycycline (DOX)-inducible CARD8 WT, E274R, and/or S297A were induced with 100 ng/mL DOX for 16 h prior to treatment with VbP (10 μM), MeBs (10 μM), <t>VX765</t> (50 μM), Bort. (10 μM), and/or MG132 (10 μM) for 6 h. Samples were then collected for LDH release and immunoblot analyses. Note in (D) that immunoblot and LDH analyses were performed separately. Data are means ± SEM of three biological replicates. All data, including immunoblots, are representative of three or more independent experiments. ***p < 0.001, **p < 0.01, *p < 0.05 by two-sided Student’s t test. n.s., not significant. See also Figure S2.
Caspase 1 Inhibitor Vx 765 Ct Vx765, supplied by ChemieTek LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/caspase-1 inhibitor vx-765 ct-vx765/product/ChemieTek LLC
Average 90 stars, based on 1 article reviews
caspase-1 inhibitor vx-765 ct-vx765 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Cedarlane vx-765
HCT116 epithelial cells were treated with 2µM of pan-caspase inhibitor Z-VAD-FMK (a-c), siRNA targeting caspase-4 (d,e) or with caspase-1/4 specific inhibitor <t>VX-765</t> (j-l). C2bbe1 epithelial cell double caspase-1 or 5 and GSDMD knockdowns were generated as indicated (f-i). For inflammasome activation, cells were electroporated with 2µg LPS. Cell death was measured by LDH cytotoxicity assay(a). Western blots to assess inflammasome activation were conducted on whole protein lysates (d, f, h, j). IL-18 release was measured by ELISA on supernatant alone (b, k). Total IL-18 production was measured by lysing cells into supernatant prior to ELISA (c, e, g, i, l). Representative of at least 3 experiments, data displayed as mean ± S.E.M. ****p<0.001, ***p<0.005.
Vx 765, supplied by Cedarlane, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vx-765/product/Cedarlane
Average 90 stars, based on 1 article reviews
vx-765 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Figure 6 Caspase 8 contributes to the pyroptosis induced by PARP inhibition. Ratios of PI+ annexin V+ OVCAR8 (A), A2780 (B), and primary homologous recombination deficiency (HRD) ovarian cancer (OC) tumor cells (C) on niraparib exposure in the presence or absence of caspase inhibitors, including VX765, Z-DEVD-FMK, Z-IETD-FMK, and Z-VAD-FMK. (D) Determination of activated caspase 3 and caspase 8 levels in OVCAR8 and A2780 cells after olaparib and niraparib treatment by flow cytometry. Histological analyses of activated caspase 3 and caspase 8 in OC patient-derived xenograft (PDX) tumors (E) and triple-negative breast cancer (TNBC) PDX tumors (F) with or without niraparib exposure (n=5/6). (G) Western blotting analyses of the cleavage of caspase 8/3 and GSDMD/E in OVCAR8 and A2780 cells on niraparib treatment in the presence or absence of caspase inhibitors, including Z-DEVD-FMK, Z-IETD-FMK, and Z-VAD-FMK. Representative images of OVCAR8 (H) and A2780 cells (I) on niraparib treatment in the presence or absence of caspase inhibitors, including VX765, Z-DEVD-FMK, and Z-IETD-FMK. Mean values±SEM. *P<0.05, **p<0.01, and ***p< 0.001 by Student’s t-test in (A–C) and (E,F).

Journal: Journal for immunotherapy of cancer

Article Title: PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF-caspase 8-GSDMD/E axis in ovarian cancer.

doi: 10.1136/jitc-2024-009032

Figure Lengend Snippet: Figure 6 Caspase 8 contributes to the pyroptosis induced by PARP inhibition. Ratios of PI+ annexin V+ OVCAR8 (A), A2780 (B), and primary homologous recombination deficiency (HRD) ovarian cancer (OC) tumor cells (C) on niraparib exposure in the presence or absence of caspase inhibitors, including VX765, Z-DEVD-FMK, Z-IETD-FMK, and Z-VAD-FMK. (D) Determination of activated caspase 3 and caspase 8 levels in OVCAR8 and A2780 cells after olaparib and niraparib treatment by flow cytometry. Histological analyses of activated caspase 3 and caspase 8 in OC patient-derived xenograft (PDX) tumors (E) and triple-negative breast cancer (TNBC) PDX tumors (F) with or without niraparib exposure (n=5/6). (G) Western blotting analyses of the cleavage of caspase 8/3 and GSDMD/E in OVCAR8 and A2780 cells on niraparib treatment in the presence or absence of caspase inhibitors, including Z-DEVD-FMK, Z-IETD-FMK, and Z-VAD-FMK. Representative images of OVCAR8 (H) and A2780 cells (I) on niraparib treatment in the presence or absence of caspase inhibitors, including VX765, Z-DEVD-FMK, and Z-IETD-FMK. Mean values±SEM. *P<0.05, **p<0.01, and ***p< 0.001 by Student’s t-test in (A–C) and (E,F).

Article Snippet: VX765 (Inh vx765i) was supplied by Invivogen.

Techniques: Inhibition, Homologous Recombination, Flow Cytometry, Derivative Assay, Western Blot

Ferroptosis inhibitor Fer-1 inhibited MHV-A59 induced syncytia and membrane damage. (A and B) Primary peritoneal macrophages (PMs) were infected with MHV-A59 at 0.05 MOI. After 2 hours of infection, cells were treated with Fer-1 (10 μM). After 24 hours of infection, cells were imaged using CytoSMART system (A) and cell confluence was evaluated using the CytoSMART website (B). (C) PMs were infected as described in (A) and were stained with propidium iodide (PI). After staining cells were imaged under fluorescence microscope. (D) PMs were infected as described in (A), followed by the treatment with Fer-1 (10 μM), z-DEVD-FMK (25 μM), VX-765 (30 μM) or GSK-872 (10 μM). Cells were stained with PI and imaged under fluorescence microscope. (E) Scale bars: For (A) and (C), 200 μm. For (D), 100 μm. Data from two independent experiments was shown. *, p < 0.05; Student’s t- test. See also Video S1.

Journal: bioRxiv

Article Title: Inhibiting ACSL1 related ferroptosis restrains MHV-A59 infection

doi: 10.1101/2021.10.14.464337

Figure Lengend Snippet: Ferroptosis inhibitor Fer-1 inhibited MHV-A59 induced syncytia and membrane damage. (A and B) Primary peritoneal macrophages (PMs) were infected with MHV-A59 at 0.05 MOI. After 2 hours of infection, cells were treated with Fer-1 (10 μM). After 24 hours of infection, cells were imaged using CytoSMART system (A) and cell confluence was evaluated using the CytoSMART website (B). (C) PMs were infected as described in (A) and were stained with propidium iodide (PI). After staining cells were imaged under fluorescence microscope. (D) PMs were infected as described in (A), followed by the treatment with Fer-1 (10 μM), z-DEVD-FMK (25 μM), VX-765 (30 μM) or GSK-872 (10 μM). Cells were stained with PI and imaged under fluorescence microscope. (E) Scale bars: For (A) and (C), 200 μm. For (D), 100 μm. Data from two independent experiments was shown. *, p < 0.05; Student’s t- test. See also Video S1.

Article Snippet: VX-765 (T6090), z-DEVD-FMK (T6005), GSK-872 (T4074), and JSH-23 (T1930) were from Targetmol.

Techniques: Infection, Staining, Fluorescence, Microscopy

Inflammasome inhibitors delay VPRH-mediated cell death. Approximately 3.5*10 4 wild-type BMDMs were seeded into 96-well plates in triplicate, and were primed using LPS (100 ng/ml) for 3 h prior to infection with V. proteolyticus mutants at MOI 50. Where indicated, inflammasome inhibitors – Vx765 (25 μM), MCC950 (20 μM), or NSA (20 μM), with the addition of propidium iodide (PI) (1 μg/ml), were added to the cells 30 min prior to bacterial infection. DMSO was added as the solvent control. (A) PI uptake was assessed using real-time microscopy (IncucyteZOOM) and then graphed as the percentage of PI-positive cells normalized to the number of cells in wells. Data are presented as the mean ± SD; n = 3. (B) Summary of normalized AUC for three independent biological experiments shown in panel A. (C-E) Cell lysates and supernatants from experiments described in A were collected 6 h post-infection. (C, D) IL-1β (C) and TNFα (D) secretion were measured using commercial ELISA kits. (E, F) Inflammasome components, caspase-1 (Casp1), GSDMD, and IL-1β cleavage were detected in BMDM lysates (E) and supernatants (F) using immunoblots (the numbers on the right of each blot indicate the blot number). The data in A, E, and F are representative of 3 independent experiments. Statistical comparisons in B, C and D between the different bacterial mutants and inflammasome inhibitors were carried using RM two-way ANOVA, followed by Tukey's multiple comparison test; the results are presented as the mean (bars) ± SD of 3 independent experiments; significant differences are denoted only for comparisons between inhibitors in each infected strain; * P < 0.05, ** P < 0.01.

Journal: Emerging Microbes & Infections

Article Title: Vibrio pore-forming leukocidin activates pyroptotic cell death via the NLRP3 inflammasome

doi: 10.1080/22221751.2020.1720526

Figure Lengend Snippet: Inflammasome inhibitors delay VPRH-mediated cell death. Approximately 3.5*10 4 wild-type BMDMs were seeded into 96-well plates in triplicate, and were primed using LPS (100 ng/ml) for 3 h prior to infection with V. proteolyticus mutants at MOI 50. Where indicated, inflammasome inhibitors – Vx765 (25 μM), MCC950 (20 μM), or NSA (20 μM), with the addition of propidium iodide (PI) (1 μg/ml), were added to the cells 30 min prior to bacterial infection. DMSO was added as the solvent control. (A) PI uptake was assessed using real-time microscopy (IncucyteZOOM) and then graphed as the percentage of PI-positive cells normalized to the number of cells in wells. Data are presented as the mean ± SD; n = 3. (B) Summary of normalized AUC for three independent biological experiments shown in panel A. (C-E) Cell lysates and supernatants from experiments described in A were collected 6 h post-infection. (C, D) IL-1β (C) and TNFα (D) secretion were measured using commercial ELISA kits. (E, F) Inflammasome components, caspase-1 (Casp1), GSDMD, and IL-1β cleavage were detected in BMDM lysates (E) and supernatants (F) using immunoblots (the numbers on the right of each blot indicate the blot number). The data in A, E, and F are representative of 3 independent experiments. Statistical comparisons in B, C and D between the different bacterial mutants and inflammasome inhibitors were carried using RM two-way ANOVA, followed by Tukey's multiple comparison test; the results are presented as the mean (bars) ± SD of 3 independent experiments; significant differences are denoted only for comparisons between inhibitors in each infected strain; * P < 0.05, ** P < 0.01.

Article Snippet: Necrosulfinamide (NSA) was purchased from Tocris Bioscience; Vx765 and MCC950 were purchased from Invitrogen.

Techniques: Infection, Solvent, Control, Microscopy, Enzyme-linked Immunosorbent Assay, Western Blot, Comparison

Inflammasome inhibitors delay VPRH-mediated cell death in human PBMCs. Approximately 2*10 4 healthy donor PBMCs were seeded into 96-well plates in triplicate for 18 h prior to infection with V. proteolyticus mutants at MOI 50. Where indicated, inflammasome inhibitors – Vx765 (25 μM) or MCC950 (20 μM), with the addition of propidium iodide (PI) (1 μg/ml), were added to the cells 30 min prior to bacterial infection. DMSO was added as the solvent control. In donor 1, only the inhibitor VX765 was applied. (A) PI uptake was assessed using real-time microscopy (IncucyteZOOM) and then graphed as the percentage of PI-positive cells normalized to the number of cells in wells. Data are presented as the mean ± SD; n = 3. (B) Summary of normalized AUC for the three donors shown in panel A. (C) Supernatants from experiments described in A were collected 4 h post-infection, and IL-1β secretion was measured using commercial ELISA kit. Statistical comparisons in B and C between the different bacterial mutants and inflammasome inhibitors were carried using RM two-way ANOVA, followed by Tukey's multiple comparison test; the results are presented as the mean (bars) ± SD of 3 independent experiments; significant differences are denoted only for the comparisons between PBMCs infected with WT V. proteolyticus and the other condition; ** P < 0.01.

Journal: Emerging Microbes & Infections

Article Title: Vibrio pore-forming leukocidin activates pyroptotic cell death via the NLRP3 inflammasome

doi: 10.1080/22221751.2020.1720526

Figure Lengend Snippet: Inflammasome inhibitors delay VPRH-mediated cell death in human PBMCs. Approximately 2*10 4 healthy donor PBMCs were seeded into 96-well plates in triplicate for 18 h prior to infection with V. proteolyticus mutants at MOI 50. Where indicated, inflammasome inhibitors – Vx765 (25 μM) or MCC950 (20 μM), with the addition of propidium iodide (PI) (1 μg/ml), were added to the cells 30 min prior to bacterial infection. DMSO was added as the solvent control. In donor 1, only the inhibitor VX765 was applied. (A) PI uptake was assessed using real-time microscopy (IncucyteZOOM) and then graphed as the percentage of PI-positive cells normalized to the number of cells in wells. Data are presented as the mean ± SD; n = 3. (B) Summary of normalized AUC for the three donors shown in panel A. (C) Supernatants from experiments described in A were collected 4 h post-infection, and IL-1β secretion was measured using commercial ELISA kit. Statistical comparisons in B and C between the different bacterial mutants and inflammasome inhibitors were carried using RM two-way ANOVA, followed by Tukey's multiple comparison test; the results are presented as the mean (bars) ± SD of 3 independent experiments; significant differences are denoted only for the comparisons between PBMCs infected with WT V. proteolyticus and the other condition; ** P < 0.01.

Article Snippet: Necrosulfinamide (NSA) was purchased from Tocris Bioscience; Vx765 and MCC950 were purchased from Invitrogen.

Techniques: Infection, Solvent, Control, Microscopy, Enzyme-linked Immunosorbent Assay, Comparison

(A) Schematic of the experiment to assess DPP9-CARD8 ternary complex displacement in cells. (B) HEK 293TCASP1+GSDMD cells were transiently transfected plasmids encoding dTAG-CARD8ZUC and the isolated FIINDSA 48 h prior to treatment with dTAG-13 (500 nM), VbP (10 μM), MeBs (10 μM), or the combination for 6 h. Samples were collected and analyzed by immunoblotting and LDH release. (C) DPP8−/−/DPP9−/− THP-1 cells were treated with MeBs (10 μM) and/or bortezomib (Bort., 10 μM) for 8 h before LDH and immunoblot analyses. (D and E) CARD8−/− THP-1 cells stably containing doxycycline (DOX)-inducible CARD8 WT, E274R, and/or S297A were induced with 100 ng/mL DOX for 16 h prior to treatment with VbP (10 μM), MeBs (10 μM), VX765 (50 μM), Bort. (10 μM), and/or MG132 (10 μM) for 6 h. Samples were then collected for LDH release and immunoblot analyses. Note in (D) that immunoblot and LDH analyses were performed separately. Data are means ± SEM of three biological replicates. All data, including immunoblots, are representative of three or more independent experiments. ***p < 0.001, **p < 0.01, *p < 0.05 by two-sided Student’s t test. n.s., not significant. See also Figure S2.

Journal: Cell reports

Article Title: Protein folding stress potentiates NLRP1 and CARD8 inflammasome activation

doi: 10.1016/j.celrep.2022.111965

Figure Lengend Snippet: (A) Schematic of the experiment to assess DPP9-CARD8 ternary complex displacement in cells. (B) HEK 293TCASP1+GSDMD cells were transiently transfected plasmids encoding dTAG-CARD8ZUC and the isolated FIINDSA 48 h prior to treatment with dTAG-13 (500 nM), VbP (10 μM), MeBs (10 μM), or the combination for 6 h. Samples were collected and analyzed by immunoblotting and LDH release. (C) DPP8−/−/DPP9−/− THP-1 cells were treated with MeBs (10 μM) and/or bortezomib (Bort., 10 μM) for 8 h before LDH and immunoblot analyses. (D and E) CARD8−/− THP-1 cells stably containing doxycycline (DOX)-inducible CARD8 WT, E274R, and/or S297A were induced with 100 ng/mL DOX for 16 h prior to treatment with VbP (10 μM), MeBs (10 μM), VX765 (50 μM), Bort. (10 μM), and/or MG132 (10 μM) for 6 h. Samples were then collected for LDH release and immunoblot analyses. Note in (D) that immunoblot and LDH analyses were performed separately. Data are means ± SEM of three biological replicates. All data, including immunoblots, are representative of three or more independent experiments. ***p < 0.001, **p < 0.01, *p < 0.05 by two-sided Student’s t test. n.s., not significant. See also Figure S2.

Article Snippet: VX765 , Cayman , 28825.

Techniques: Transfection, Isolation, Western Blot, Stable Transfection

KEY RESOURCES TABLE

Journal: Cell reports

Article Title: Protein folding stress potentiates NLRP1 and CARD8 inflammasome activation

doi: 10.1016/j.celrep.2022.111965

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: VX765 , Cayman , 28825.

Techniques: Recombinant, LDH Cytotoxicity Assay, Enzyme-linked Immunosorbent Assay, Viability Assay, Cytotoxicity Assay, Software

KEY RESOURCES TABLE

Journal: Cell reports

Article Title: Protein folding stress potentiates NLRP1 and CARD8 inflammasome activation

doi: 10.1016/j.celrep.2022.111965

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: VX765 , Cayman , 28825.

Techniques: Recombinant, LDH Cytotoxicity Assay, Enzyme-linked Immunosorbent Assay, Viability Assay, Cytotoxicity Assay, Software

HCT116 epithelial cells were treated with 2µM of pan-caspase inhibitor Z-VAD-FMK (a-c), siRNA targeting caspase-4 (d,e) or with caspase-1/4 specific inhibitor VX-765 (j-l). C2bbe1 epithelial cell double caspase-1 or 5 and GSDMD knockdowns were generated as indicated (f-i). For inflammasome activation, cells were electroporated with 2µg LPS. Cell death was measured by LDH cytotoxicity assay(a). Western blots to assess inflammasome activation were conducted on whole protein lysates (d, f, h, j). IL-18 release was measured by ELISA on supernatant alone (b, k). Total IL-18 production was measured by lysing cells into supernatant prior to ELISA (c, e, g, i, l). Representative of at least 3 experiments, data displayed as mean ± S.E.M. ****p<0.001, ***p<0.005.

Journal: bioRxiv

Article Title: GSDMD pore formation regulates caspase-4 cleavage to limit IL-18 production in the intestinal epithelium

doi: 10.1101/2024.02.01.578487

Figure Lengend Snippet: HCT116 epithelial cells were treated with 2µM of pan-caspase inhibitor Z-VAD-FMK (a-c), siRNA targeting caspase-4 (d,e) or with caspase-1/4 specific inhibitor VX-765 (j-l). C2bbe1 epithelial cell double caspase-1 or 5 and GSDMD knockdowns were generated as indicated (f-i). For inflammasome activation, cells were electroporated with 2µg LPS. Cell death was measured by LDH cytotoxicity assay(a). Western blots to assess inflammasome activation were conducted on whole protein lysates (d, f, h, j). IL-18 release was measured by ELISA on supernatant alone (b, k). Total IL-18 production was measured by lysing cells into supernatant prior to ELISA (c, e, g, i, l). Representative of at least 3 experiments, data displayed as mean ± S.E.M. ****p<0.001, ***p<0.005.

Article Snippet: Rabbit anti-GSDMD (HPA044487; Sigma), mouse anti - Caspase-4 (M029-3, Marine BL), rabbit anti-caspase-1 (3866S; Cell Signalling Technology), rabbit anti-Caspase-5 (ab40887; abcam), goat anti-IL-18 (AF2548; Novus Biologicals), LPS (14011S; CST), human IFNγ (80385S; Cell Signalling Technology), Nigericin (N7143; Sigma), Flagellin (tlrl-epstfla; InvivoGen), Z-VAD-FMK (tlrl-vad; InvivoGen), VX-765 (7143/50, Cedarlane), peroxidase conjugated anti-rabbit and anti-mouse secondaries (Jackson Labs, 111-035-003), peroxidase conjugated anti-goat secondary (HAF109; R&D Systems).

Techniques: Generated, Activation Assay, LDH Cytotoxicity Assay, Western Blot, Enzyme-linked Immunosorbent Assay